Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors

NCT03510104 is registered in ClinicalTrials.gov with Meryx, Inc. as lead sponsor.

NCT NCT03510104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03510104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
Lead sponsor
Meryx, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 22, 2018
Completion date
December 31, 2025
Enrollment
42 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, metastatic cancer, neoplasm metastasis, neoplasms, neoplastic processes, pathologic processes